Methods and Compositions for Reducing Ischemic Injury of the Heart by Administering Adenosine A3 and Adenosine A1 Receptor Agonists
Description of Invention:
This technology relates to methods of administering compounds to protect the heart from ischemic injury. In particular, this invention provides agonists which selectively activate adenosine A3 and A1 receptors simultaneously, thereby enhancing the protective effects of preconditioning and rendering the myocardium more resistant to ischemia. This invention involves administration of specific A1 and A3 agonists during ischemic attacks, or at risk for ischemic damage. The agonists of the invention may be delivered prior to a surgical procedure, and may also be administered to a patient to prevent or reduce the severity of ischemic damage during surgery. Additionally, the A3/A1 agonists may be administered following surgical procedures to reduce the risk of post-surgical ischemic complications. The A3 and A1 agonists may be administered to patients with angina, which may be chronic and stable, unstable or due to post-myocardial infarction.
Inventors:
KA Jacobson BT Liang (NIDDK)
Patent Status:
DHHS Reference No. E-006-98/0 filed 09 May 1997
Portfolios: Internal Medicine Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Other Internal Medicine-Therapeutics-Cardiology-Other Central Nervous System -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Tara L. Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4426
Email: tarak@mail.nih.gov
Fax: (301)402-0220
